Alira Health

Alira Health

XV Congresso Nazionale Sihta

October 25-27, 2022 | Rome, Italy

We are pleased to share that we will be joining as speakers and sponsors XV Congresso Nazionale Sihta, a key event for Italian Healthcare industry.

Our speeches:
Digital Health e Real World Evidence: Valutazione di un modello a supporto di processi decisionali in ambito HTA

English title:
Digital Health and Real World Evidence: Evaluation of the Decision-Making Model in HTA

Authors:
Firenze G. Monterosso A, Romeo J.

Presented by:
Giovanni Firenze, Market Access and Pricing Director, Italy, Alira Health

Presentation time:
October 26, 16.30-17.30 CEST

Similitudini e differenze tra EUnetHTA e HTA nazionali: Aree di interesse per la futura metodologia HTA Europea

English title:
Similarities and Differences Between EUnetHTA and HTAs: Areas of Interest for the Future European HTA Methodology

Authors:
Rabadi L, Couillerot AL, De la Paz I, Rodriguez N, Asmah A, Aguado M, Belamri M, Ottobrino V, Mangone M.

Presented by:
Monica Mangone, Global Market Access Senior Consultant, Alira Health

Presentation time:
October 26, 16.30-17.30 CEST

Events
Published on:
September 30, 2022
Our Speakers:
Giovanni Firenze

Giovanni Firenze

Market Access and Pricing Director, Italy, Alira Health Giovanni has started his career in Eli Lilly in Germany and in the UK as a Manager of a Sales & Marketing European Project, moving thereafter to Bristol Myers Squibb in the USA and later in Italy covering European positions.

In 2002, he joined the management consulting arena working for Arthur D. Little International, IMS Health Consulting Group (UK), as a Director, Executive Insight (Switzerland), HBI and Vintura.

During his career, Giovanni carried out and led multiple projects in different Therapeutic Areas, such as Respiratory, Cardiology, Oncology, Hematology, GI, Rare Diseases and CNS for pharma and biotech companies. His consulting experience extends also to the molecules and digital health solutions.

Giovanni holds a MS degree in Engineering from the University of Genoa and an MBA from SDA Bocconi and University of Michigan – Stephen Ross Business School.
Monica Mangone

Monica Mangone

Global Market Access Senior Consultant, Alira Health Experienced Market Access professional with 15+ years of experience in Healthcare and Pharmaceutical Industries, Monica worked at Novartis, Amgen and AstraZeneca prior to joining Alira Health.

Monica also managed several Dossier of P&R negotiations with AIFA, executed robust cross-functional National International and regional market access plan to support launches of new products (oncology and rare disease included).

Monica holds a BSc in Science and MSc in Health Economics from University of Milan, is currently a member of the HBA Healthcare Businesswomen's Association, and has been an ICF certified coach since 2000.
Our Delegates:
Andrea Mantovani

Andrea Mantovani

Vice President, Global Market Access and Pricing, Alira Health
Veronica Ottobrino

Veronica Ottobrino

Analyst, Global Market Access, Alira Health

Would you like to meet Alira Health at XV Congresso Nazionale Sihta? Contact us to set up a meeting.

Related news

Articles June 6, 2024
The Role of Real-World Data in the Development of Lupus Solutions
This article explores the benefits of RWD in lupus, the value of leveraging RWD throughout the lupus product lifecycle, and the RWD sources available in this indication.
Lupus Real-World Evidence (RWE)
Events April 24, 2024
MGFA National Patient Conference 2024
We are pleased to share that we will be participating in MGFA National Patient Conference 2024 as speakers and exhibitors.
Digital Health Innovation Myasthenia Gravis (MG) Patient Engagement Rare Disease
Reports April 17, 2024
LENMELDY Approval by FDA Relied on RWE
The FDA recently approved LENMELDY® (atidarsagene autotemcel), a gene therapy indicated for the treatment of metachromatic leukodystrophy (MLD), a rare disease, based on RWE.
Real-World Evidence (RWE) RWE Decision Alert
Reports April 11, 2024
The Spanish AEMPS Approves EBVALLO, Supported by Effectiveness and Safety Data from RWE
On February 8, 2024, the Spanish Agency for Medicines (AEMPS) approved EBVALLO® (tabelecleucel) for the treatment of lymphoproliferative disorders, leveraging effectiveness and safety(...)
Real-World Evidence (RWE) RWE Decision Alert
Events March 27, 2024
ISPOR 2024
We are excited to announce that we will attend and present posters at ISPOR 2024, the leading global conference for HEOR.
HEOR Lupus Real-World Evidence (RWE)
News March 27, 2024
Alira Health Joins Forces with APMA to Advance Podiatric Registry
Alira Health joined the American Podiatric Medical Association (APMA), the largest professional association representing podiatrists, physicians and surgeons who treat the foot and(...)
Real-World Evidence (RWE) Registry-based studies Research and Development Wound Healing
Events February 20, 2024
World EPA Congress Europe
Look for market access and pricing experts Ahmad Bechara and Andrea Mantovani representing Alira Health on the agenda at World EPA Congress.
Market Access Pricing Real-World Evidence (RWE)
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.